ReviewCancers2021
Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 42 citations in OpenAlex.
- The Adjuvant-Phase Dilemma After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC: Evidence and Response-Guided Strategies.Cancers · 2026Review
- Multi-modal circulating cell-free DNA profiling to predict response to docetaxel in metastatic castration-resistant prostate cancer.NPJ precision oncology · 2026Article
- Multimodal plasma and urinary cell-free DNA profiling improves risk stratification in newly diagnosed prostate cancer.NPJ precision oncology · 2026Article
- DNA methylation biomarkers for the diagnosis and treatment management of breast cancer: where are we now?Epigenomics · 2025Review
- Review
- Multimodal analysis of cell-free DNA enhances differentiation of early-stage breast cancer from benign lesions and healthy individuals.BMC biology · 2025Article
- Challenges and proposed solutions to the adoption of cell free DNA in screening, detecting and prognosticating colorectal cancer.World journal of gastrointestinal oncology · 2025Review
- A new reality of molecular surveillance for resected lung cancer.Translational lung cancer research · 2025Article
- Innovative approach to the detection of circulating tumor biomarkers: multi-dimensional application of liposome technology.Lipids in health and disease · 2025Review
- DNA Methylation in Urine and Feces Indicative of Eight Major Human Cancer Types Globally.Life (Basel, Switzerland) · 2025Review
- Review
- Understanding the Landscape of Multi-Cancer Detection Tests: The Current Data and Clinical Considerations.Life (Basel, Switzerland) · 2024Review
- Innovation in Non-Invasive Diagnosis and Disease Monitoring for Meningiomas.International journal of molecular sciences · 2024Review
- Article
- Towards effectiveness of cell free DNA based liquid biopsy in head and neck squamous cell carcinoma.Scientific reports · 2024Article
- Cell-free DNA in the management of prostate cancer: Current status and future prospective.Asian journal of urology · 2023Review
- Identification of Somatic Mutations in Plasma Cell-Free DNA from Patients with Metastatic Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2023Article
- Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance.Molecular cancer · 2023Review
- Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer.Exploration of targeted anti-tumor therapy · 2023Review
- MonitoringFrontiers in oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-free DNA (cfDNA) analysis using liquid biopsies is a non-invasive method to gain insights into the biology, therapy response, mechanisms of acquired resistance and therapy escape of various tumors. While it is well established that individual cancer treatment options can be adjusted by panel next-generation sequencing (NGS)-based evaluation of driver mutations in cfDNA, emerging research additionally explores the value of deep characterization of tumor cfDNA genomics and fragmentomics as well as nucleosome modifications (chromatin structure), and methylation patterns (epigenomics) for comprehensive and multi-modal assessment of cfDNA. These tools have the potential to improve disease monitoring, increase the sensitivity of minimal residual disease identification, and detection of cancers at earlier stages. Recent progress in emerging technologies of cfDNA analysis is summarized, the added potential clinical value is highlighted, strengths and limitations are identified and compared with conventional targeted NGS analysis, and current challenges and future directions are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.